Monte Rosa Therapeutics Inc’s recent filing unveils that its Principal Accounting Officer Dunn Edmund unloaded Company’s shares for reported $9174.0 on Jun 03 ’25. In the deal valued at $4.45 per share,2,062 shares were sold. As a result of this transaction, Dunn Edmund now holds 23,732 shares worth roughly $0.12 million.
Then, Leo Chandra P. bought 10,000 shares, generating $58,383 in total proceeds. Upon buying the shares at $5.84, the Director now owns 10,000 shares.
Before that, Versant Venture Capital VI, L. sold 89,990 shares. Monte Rosa Therapeutics Inc shares valued at $869,240 were divested by the 10% Owner at a price of $9.66 per share. As a result of the transaction, Versant Venture Capital VI, L. now holds 2,007,948 shares, worth roughly $10.2 million.
Wells Fargo downgraded its Monte Rosa Therapeutics Inc [GLUE] rating to an Equal weight from a an Overweight in a research note published on December 19, 2024; the price target was decreased to $11 from $14. A number of analysts have revised their coverage, including Wedbush’s analysts, who began to cover the stock in mid February with a ‘”an Outperform”‘ rating. Wells Fargo also remained covering GLUE and has increased its forecast on January 03, 2023 with a “an Overweight” recommendation from previously “an Equal weight” rating. UBS started covering the stock on October 13, 2022. It rated GLUE as “a Buy”.
Price Performance Review of GLUE
On Tuesday, Monte Rosa Therapeutics Inc [NASDAQ:GLUE] saw its stock jump 3.25% to $5.08. Over the last five days, the stock has gained 9.48%. Monte Rosa Therapeutics Inc shares have fallen nearly -26.80% since the year began. Nevertheless, the stocks have risen 21.24% over the past one year.
How much short interest is there in Monte Rosa Therapeutics Inc?
A steep rise in short interest was recorded in Monte Rosa Therapeutics Inc stocks on 2025-05-15, growing by 0.86 million shares to a total of 8.4 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 7.53 million shares. There was a rise of 10.29%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on August 15, 2022 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $20 price target.
